Evidence map›Paper›PMID 39598459›Full record

ArticlePharmaceuticals (Basel, Switzerland)2024

Artificial Intelligence and Machine Learning Models for Predicting Drug-Induced Kidney Injury in Small Molecules.

Mohan Rao, Vahid Nassiri, Sanjay Srivastava, Amy Yang, Satjit Brar, Eric McDuffie, Clifford Sachs

Abstract read
In one paragraph

Article in Pharmaceuticals (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. AI snake oil? A risk/benefit analysis for toxicology.Frontiers in artificial intelligence · 2026
    Article
  6. Article
  7. Article
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Mohan RaoPreclinical and Clinical Pharmacology and Chemistry, Neurocrine Biosciences, San Diego, CA 92130, USA.ORCID 0000-0001-7395-5260
Vahid NassiriOpen Analytics NV, Jupiterstraat 20, 2600 Antwerp, Belgium.
Sanjay SrivastavaPreclinical and Clinical Pharmacology and Chemistry, Neurocrine Biosciences, San Diego, CA 92130, USA.
Amy YangPreclinical and Clinical Pharmacology and Chemistry, Neurocrine Biosciences, San Diego, CA 92130, USA.
Satjit BrarPreclinical and Clinical Pharmacology and Chemistry, Neurocrine Biosciences, San Diego, CA 92130, USA.
Eric McDuffiePreclinical and Clinical Pharmacology and Chemistry, Neurocrine Biosciences, San Diego, CA 92130, USA.
Clifford SachsPreclinical and Clinical Pharmacology and Chemistry, Neurocrine Biosciences, San Diego, CA 92130, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND/

objectivesDrug-Induced Kidney Injury (DIKI) presents a significant challenge in drug development, often leading to clinical-stage failures. The early prediction of DIKI risk can improve drug safety and development efficiency. Existing models tend to focus on physicochemical properties alone, often overlooking drug-target interactions crucial for DIKI. This study introduces an AI/ML (artificial intelligence/machine learning) model that integrates both physicochemical properties and off-target interactions to enhance DIKI prediction.

methodsWe compiled a dataset of 360 FDA-classified compounds (231 non-nephrotoxic and 129 nephrotoxic) and predicted 6064 off-target interactions, 59% of which were validated in vitro. We also calculated 55 physicochemical properties for these compounds. Machine learning (ML) models were developed using four algorithms: Ridge Logistic Regression (RLR), Support Vector Machine (SVM), Random Forest (RF), and Neural Network (NN). These models were then combined into an ensemble model for enhanced performance.

resultsThe ensemble model achieved an ROC-AUC of 0.86, with a sensitivity and specificity of 0.79 and 0.78, respectively. The key predictive features included 38 off-target interactions and physicochemical properties such as the number of metabolites, polar surface area (PSA), pKa, and fraction of Sp3-hybridized carbons (fsp3). These features effectively distinguished DIKI from non-DIKI compounds.

conclusionsThe integrated model, which combines both physicochemical properties and off-target interaction data, significantly improved DIKI prediction accuracy compared to models that rely on either data type alone. This AI/ML model provides a promising early screening tool for identifying compounds with lower DIKI risk, facilitating safer drug development.

Indexed as

artificial intelligencecheminformaticscomputational toxicologydrug induced kidney injurymachine learningoff-target interactions

Identifiers

PMID39598459
PMCPMC11597314

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.